By Stephen Nakrosis
Shares of Idera Pharmaceuticals Inc. were trading higher in Wednesday's after-hours market, following news that the company acquired privately held Aceragen Inc.
At 5:51 p.m. ET, Idera's shares had risen 17.76% to trade at 47 cents a share. Volume at the time topped 101,000 shares. The stock finished the day's regular session with a 3.73% gain, closing at 38 cents per share.
The acquisition includes ACG-701, "a proprietary formulation of sodium fusidate being developed as a potential treatment for acute pulmonary exacerbations associated with cystic fibrosis and for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen," Idera said.
Additionally, the acquisition includes ACG-801, an "investigational biologic enzyme replacement therapy being developed for the treatment of Farber disease," the company said.
Idera also named John Taylor, the former chief executive of Aceragen, to succeed CEO Vincent Milano, who was named chair of the board.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2022 18:15 ET (22:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。